Ono picks up Japan Relistor rights
This article was originally published in Scrip
Executive Summary
Onohas acquired exclusive Japanese rights to develop and commercialiseProgenics Pharmaceuticals' mu-opioid receptor antagonist Relistor (methylnaltrexone bromide), for $15 million up front and up to $20 million in development milestones. Ono will also pay sales-based royalties that analysts say could exceed the rate paid by Wyeth, Progenics' partner for Relistor outside Japan, and commercialisation milestones, which could be worth up to a further $20 million.